glucose, (beta-d)-isomer has been researched along with Cholangiocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y; Li, W; Ming, Y; Xiao, L; Zheng, Z | 1 |
| Dowlati, A; Gerson, SL; Hoppel, CL; Ingalls, ST; Ivy, P; Li, X; Majka, S; Remick, SC; Sedransk, N; Spiro, T | 1 |
1 trial(s) available for glucose, (beta-d)-isomer and Cholangiocarcinoma
| Article | Year |
|---|---|
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antineoplastic Agents; Carbazoles; Cholangiocarcinoma; Disease Progression; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Glucosides; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia | 2001 |
1 other study(ies) available for glucose, (beta-d)-isomer and Cholangiocarcinoma
| Article | Year |
|---|---|
Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hydrolyzable Tannins; In Vitro Techniques; Mice; Mice, Nude; Receptors, Notch; Signal Transduction; Transcription Factor HES-1; Xenograft Model Antitumor Assays | 2016 |